Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9927
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc (SNSS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Equity Offering 14
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 26
Asset Transactions 27
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 27
Sunesis Pharmaceuticals Inc – Key Competitors 29
Sunesis Pharmaceuticals Inc – Key Employees 30
Sunesis Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36
Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38
Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40
May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42
Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44
Corporate Communications 46
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47
Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48
Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49
Legal and Regulatory 50
Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50
Product News 51
12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51
07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52
Product Approvals 53
May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53
Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56
Clinical Trials 57
Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 26
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 27
Sunesis Pharmaceuticals Inc, Key Competitors 29
Sunesis Pharmaceuticals Inc, Key Employees 30
Sunesis Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SkinMedica Inc-製薬・医療分野:企業M&A・提携分析
    Summary SkinMedica Inc (SkinMedica) is a manufacturer and distributor of skin care products. The company’s products include purifying foaming wash, facial cleanser, skin polisher, purifying toner, TNS recovery complex, uplifting eye serum, restorative ointment, dermal repair cream, and post procedur …
  • Printpack, Inc.:企業の戦略・SWOT・財務情報
    Printpack, Inc. - Strategy, SWOT and Corporate Finance Report Summary Printpack, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SMS Pharmaceuticals Ltd (SMSPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary SMS Pharmaceuticals Ltd (SMS Pharma) is a manufacturer of active pharmaceutical ingredients (APIs) and intermediates that develops offers anti-fungal, anti-ulcer, anti-migraine, anti-hypersensitive, anti-psychotic, anti-viral and other products. Its pipeline products include Ticagrelor, Clop …
  • Channel Four Telivision Corp:企業の戦略的SWOT分析
    Channel Four Telivision Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Torrent Power Limited:企業の戦略・SWOT・財務情報
    Torrent Power Limited - Strategy, SWOT and Corporate Finance Report Summary Torrent Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sonda SA (SONDA):企業の財務・戦略的SWOT分析
    Sonda SA (SONDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PDL BioPharma Inc (PDLI):企業の財務・戦略的SWOT分析
    PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Proton Holdings Berhad:企業の戦略的SWOT分析
    Proton Holdings Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Immuno-Biological Laboratories Co Ltd (4570):製薬・医療:M&Aディール及び事業提携情報
    Summary Immuno-Biological Laboratories Co Ltd (IBL) is a pharmaceutical company that develops, manufactures and markets diagnostic products. The company provides business areas such as diagnostic and research reagents, customized services, global sales network, protein production business using tran …
  • Eesti Energia AS:戦略・SWOT・企業財務分析
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cathay Pacific Airways Limited:戦略・SWOT・企業財務分析
    Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務分析
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Equinox Energy Capital Ltd:電力:M&Aディール及び事業提携情報
    Summary Equinox Energy Capital Ltd (Equinox) is an investment management firm that invests in wind and renewable energy assets. The firm spans its expertise in permitting, construction and asset management. It acquires PV plants which have existing project finance, lease or mortgage financing. Equin …
  • Cabot Oil & Gas Corporation (COG)-石油・ガス分野:企業M&A・提携分析
    Summary Cabot Oil & Gas Corporation (Cabot) is an independent oil and gas company, which develops, and explores for oil and gas properties primarily in the continental US. It focuses on developing natural gas resources in the Marcellus shale in northeast Pennsylvania and oil development in the Eagle …
  • Pharmacosmos AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmacosmos AS (Pharmacosmos) is a drug discovery and development company that manufactures and markets medicines for the treatment of iron deficiency anaemia in humans and animals. The company offers human iron therapy, veterinary iron therapy, pharmacosmos dextrans, pharmaceutical biopoly …
  • Booking Holdings Inc:企業の戦略・SWOT・財務分析
    Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Greensmith Energy Management Systems LLC-エネルギー分野:企業M&A・提携分析
    Summary Greensmith Energy Management Systems, LLC (Greensmith) is a provider of energy storage management and services. The company specializes in software and control solutions to operate and manage Distributed Energy Storage Systems (DESS) for utility-scale, C&I or Micro-grid deployments. It offer …
  • Paragon Offshore plc (PGN):企業の財務・戦略的SWOT分析
    Summary Paragon Offshore Plc (Paragon Offshore) is an oil and gas company that offers offshore drilling rigs. The company provides contract drilling, maintenance and fleet management services. It operates through a fleet of rigs including Jackup rigs, Drillships and semi submersible rigs. Paragon Of …
  • PricewaterhouseCoopers LLP:企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Diamondback Energy Inc (FANG):企業の財務・戦略的SWOT分析
    Summary Diamondback Energy Inc (Diamondback Energy) operates as an oil and gas company that offers exploration and development programs. The company acquires, develops, explores and exploits unconventional, onshore oil and natural gas reserves in Permian Basin in West Texas. It develops the reserves …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆